Skip to main content

AVXL

Stock
Health Care
Biotechnology

Performance overview

AVXL Price
Price Chart

Forward-looking statistics

Beta
1.18
Risk
85.72%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees34
Market cap$327.6M

Fundamentals

Enterprise value$671.4M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.56
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$10M
Avg trading volume (10 day)$13M
Put-call ratio

Macro factor sensitivity

Growth+2.3
Credit+9.0
Liquidity-0.4
Inflation-3.4
Commodities-0.7
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-17.13
Price to sales
P/E Ratio-17.13
Enterprise Value to Revenue
Price to book9.23

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research (July 10, 2025)
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga (December 26, 2024)
6 Favorite Biotech Bets For 2023

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.

Forbes (January 9, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free